Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | AXL | P30530 | 1/20 | 0.51 |
| ▸ | CHUK | O15111 | 1/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 3/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21596374 | 0.95 | KMT2A (0.56) | KMT2AAXLCHUKCSNK1A1CLK4 | |
| SCHEMBL30042311 | 0.95 | KMT2A (0.56) | KMT2AAXLCHUKCSNK1A1CLK4 | |
| SCHEMBL3150451 | 0.92 | KMT2A (0.51) | KMT2AAXLCHUKCSNK1A1CLK4 | |
| SCHEMBL13735749 | 0.84 | KMT2A (0.45) | KMT2AAXLCSNK1A1CLK4PRKCQ | |
| SCHEMBL16120965 | 0.83 | KMT2A (0.44) | KMT2AAXLCHUKCSNK1A1CLK4 | |
| SCHEMBL14657893 | 0.82 | KMT2A (0.43) | KMT2AAXLCSNK1A1CLK4PRKCQ | |
| SCHEMBL14657894 | 0.82 | KMT2A (0.43) | KMT2AAXLCSNK1A1CLK4PRKCQ | |
| SCHEMBL30662127 | 0.82 | CSNK1A1 (0.45) | KMT2AAXLCSNK1A1CLK4ALDH1A1 | |
| SCHEMBL21409882 | 0.82 | CSNK1A1 (0.45) | KMT2AAXLCSNK1A1CLK4ALDH1A1 | |
| SCHEMBL20677003 | 0.81 | KMT2A (0.57) | KMT2AAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112313207-B | Cyano-substituted pyridine and cyano-substituted pyrimidine compounds, and preparation methods and applications thereof | 北京赛特明强医药科技有限公司 | 2023-02-14 | — | — | CN | disclosed |
| CN-112313207-A | Cyano-substituted pyridine and cyano-substituted pyrimidine compounds, and preparation methods and applications thereof | 北京赛特明强医药科技有限公司 | 2021-02-02 | — | — | CN | disclosed |
| US-7825128-B2 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | BAYER SCHERING PHARMA AG (DE) | 2010-11-02 | — | — | US | disclosed |
| US-7825128-B2 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | BAYER SCHERING PHARMA AG (DE) | 2010-11-02 | — | — | US | disclosed |
| US-7825128-B2 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | BAYER SCHERING PHARMA AG (DE) | 2010-11-02 | — | — | US | disclosed |
| EP-1963282-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES , THEIR PREPARATION AND USE AS DRUGS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-09-03 | — | — | EP | disclosed |
| US-20070232632-A1 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232632-A1 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232632-A1 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| WO-2007071455-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES , THEIR PREPARATION AND USE AS DRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-06-28 | — | — | WO | disclosed |
| EP-1794134-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINES AS CELL CYCLE KINASE INHIBITORS OR RECEPTOR TYROSINE KINASE INHIBITORS, PRODUCTION OF SAID SUBSTANCES AND USE OF THE LATTER AS MEDICAMENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-06-13 | — | — | EP | disclosed |
| US-20060111378-A1 | Substituted 2-anilinopyrimidines as cell-cycle-kinase or receptor-tyrosine-kinase inhibitors, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-25 | — | — | US | disclosed |
| WO-2006034872-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINES AS CELL CYCLE KINASE INHIBITORS OR RECEPTOR TYROSINE KINASE INHIBITORS, PRODUCTION OF SAID SUBSTANCES AND USE OF THE LATTER AS MEDICAMENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111378-A1 | Substituted 2-anilinopyrimidines as cell-cycle-kinase or receptor-tyrosine-kinase inhibitors, their production and use as pharmaceutical agents | CDK2, KDR, CDK4 | KMT2A 1366/4885AXL 143/4885CHUK 163/4885 |
| US-20070232632-A1 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | TYMS, DPYD, DHFR | KMT2A 4091/4885AXL 326/4885CHUK 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.